Gut Works® Effectiveness Research Abstract

Real-World Effectiveness of Gut Works® for Digestive Health: User-Reported Outcomes and a Duration-Stratified Analysis from a Cross-Sectional Customer Survey

June 2026

Key Findings

1. 95.0% of users who gave a definitive rating found Gut Works® effective in supporting their digestive needs (n=141), with 46.8% rating it extremely effective and a combined negative rate of just 5.0%.
   
2. A clear duration-response relationship was observed: extremely effective ratings rose to 58.8% among users of four months or more, versus 30.8% among those using it under two months, with the combined positive rate reaching 97.6% in the longest-duration group.
   
3. 91.1% of users reported benefits in at least one area. Among those who had experienced each issue before use, benefit was reported by 62.9% for bloating, 66.1% for diarrhoea, and 60.5% for excessive wind and gas.
   
4. Advocacy was exceptionally strong: a Net Promoter Score of +57, a mean recommendation score of 8.7 out of 10, and 89.7% scoring 7 or above.
   
5. Onset of benefit was rapid: 75.4% of those reporting a timeframe noticed results within four weeks and half within three weeks.
   

Background

Digestive complaints, including bloating, irregularity, wind, and abdominal discomfort, are highly prevalent and have a substantial impact on daily comfort, energy, and quality of life. The gut microbiome is increasingly recognised as central to digestive and broader systemic health, and interest in targeted pre- and probiotic supplementation has grown accordingly. Gut Works® is a microbiome-support supplement developed by DRV+ (Formerly DR.VEGAN®), combining probiotics, prebiotics, and fibre to support digestive comfort, regularity, and gut function. This abstract reports real-world, user-reported outcomes from a cross-sectional customer survey, including overall effectiveness, a duration-stratified analysis, issue-level relief among prior sufferers, time to benefit, and likelihood to recommend.

Methods

A cross-sectional customer feedback survey was administered to DRV+ customers using Gut Works®, yielding 146 analysable responses. Respondents reported duration and consistency of use, the severity of their gut and digestive issues before starting, the specific issues experienced before use, overall effectiveness (four-point scale plus a ‘too early to say’ option), the issues from which Gut Works® had provided the most relief (multiple responses permitted), time to first results, and likelihood to recommend on a 0–10 scale. Effectiveness percentages are reported among respondents who provided a definitive rating, excluding ‘too early to say’. A pre-specified duration-stratified analysis compared effectiveness across usage-duration bands, and issue relief was calculated among the subset of respondents who had experienced each issue before use. Individual-level data were analysed for all responses.

Results

Cohort and adherence

The cohort was predominantly established and highly adherent: 58.9% had used Gut Works® for four months or more, and 96.6% took it daily (82.9%) or most days (13.7%). Before starting, the burden of digestive symptoms was substantial - 79.5% reported regular or severe gut and digestion issues, and none reported no issues at all. The most common pre-existing issues were bloating (79.5%), constipation (53.4%), excessive wind and gas (52.1%), and fatigue (45.9%), confirming a cohort with meaningful baseline digestive complaints.

Overall effectiveness

Of the 141 respondents who gave a definitive rating, 95.0% rated Gut Works® effective, 46.8% extremely effective and 48.2% somewhat effective. Only 2.8% rated it not so effective and 2.1% not at all effective, giving a combined negative rate of 5.0%. See Figure 1.

Duration-response relationship

A clear duration-dependent pattern emerged. The extremely effective rating was markedly higher among long-term users, reaching 58.8% at four months or more versus 30.8% at under two months, while the combined positive rate rose from 88.5% to 97.6% across the same range. This gradient is consistent with the biology of microbiome modulation, in which the establishment of a stable, beneficial bacterial population develops over sustained supplementation. See Figure 2.

Issue support

91.1% of all respondents reported issues in at least one area, with a mean of 2.3 issues addressed. To assess benefits precisely, the benefit rate was calculated among only those respondents who had experienced each issue before use. On this basis, Gut Works® provided support from diarrhoea in 66.1% of prior sufferers, bloating in 62.9%, and excessive wind and gas in 60.5%, with benefit rates above 56% for five of the seven most common complaints. See Figure 3.

Onset and advocacy

Onset of benefit was rapid: of the 134 respondents reporting a specific timeframe, 75.4% noticed results within four weeks and 50.0% within three weeks. Advocacy was exceptionally strong, with a mean recommendation score of 8.7 out of 10, 89.7% scoring 7 or above, and a Net Promoter Score of +57 (66.9% promoters against 10.3% detractors). See Figure 4.

Conclusions

In this real-world feedback survey of 146 consistent users, the majority with regular or severe baseline digestive issues, Gut Works® demonstrated a high user-reported effectiveness rate (95.0%), targeted benefits across the most common digestive issues, rapid onset of benefit, and outstanding advocacy (NPS +57). The duration-stratified analysis revealed a clear duration-response relationship, with the extremely-effective rating nearly doubling between short-term and long-term users and combined positive ratings approaching universal at four months or more. This pattern is coherent with the gradual establishment of a beneficial gut microbiome and underscores the value of sustained daily use, consistent with the duration-dependent benefit observed across other DRV+ supplement evaluations. The issue-level analysis, calculated specifically among prior sufferers, provides a robust, clinically meaningful read on issues addressed, with a majority of users experiencing improvement in bloating, diarrhoea, wind, and other complaints. The principal limitations are the absence of a control group, reliance on self-reported outcomes, and the predominance of established users in the cohort, which may bias the overall effectiveness figure upward relative to a treatment-naive population. Prospective, controlled studies with standardised issue instruments and defined follow-up intervals would allow these real-world signals to be confirmed and the duration-response relationship characterised formally.

Keywords: Gut Works®, gut health, digestive health, microbiome, probiotics, prebiotics, bloating, IBS symptoms, user-reported outcomes, duration-response, net promoter score, nutritional supplement

Survey date: 2024-2025  |  Respondents: N = 146  |  Adherence: 96.6% daily or most days  |  Data type: Individual-level responses   

Media enquiries: Please contact drv@thephagroup.com  |   drv.co